FoggyIsle.XYZ | Market's view on Croda International

Q1 sales figures for Croda did not meet market expectations, leading to disappointment.
Despite overall market downturns, Croda’s share price increased, which was unexpected given the circumstances.
There are evaluations suggesting Croda’s fair value is between £4.4bn and £5.6bn, indicating a potential wait-and-see approach before investing.
Croda’s stock price recovery is noted, with a current resistance at £50, but it remains far from its peak at £100 in 2021.
The company faces a long road to recovery with a reduced financial forecast for FY24 and ongoing operational challenges including inventory overhang and slower growth in large-cap customers.
There is a reference to a positive market response influenced by a broker’s report from Jefferies.
Stock has potentially hit its lowest point, signalling a long recovery phase.
The director’s purchase might be linked to anticipated positive results from a specific product test.
Croda continues to cover the chemical sector, maintaining profitability despite declining orders due to global market conditions.
The stock has experienced a significant decline of 40% since the start of 2022.
Croda issued a profit warning due to clients reducing stockpiles, marking the second profit outlook reduction in recent months.
Concerns are raised about something fundamentally wrong with the company as the stock continues to decline.
Director’s sales of shares have negatively impacted perceptions of company stability.
Stock price has halved since mid-2021, raising questions about whether it is advisable to hold or sell the shares.
Croda’s involvement in manufacturing vaccine lipids is noted, which is considered a growth market despite some contamination issues.